ClinicalTrials.gg
RecruitingNCT06407102BIONOSEUpdated Jun 16, 2026

Collection of Primary Human

An interventional study of Collection of nasal cells during programme surgery in Nasal Disease, sponsored by University Hospital, Tours. Recruiting at 1 site in France. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by University Hospital, Tours · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Treatment and prevention of respiratory infections are of great interest in many medical areas. Create a physical device covered by primary human nasal cells could be very usefull in order to analyse delivery and efficiency of drugs. In this context the aim of this project is to create a collection of primary cells from the human nasal epithelium.

This collection will be realised during programmed surgery, thanks to a specific device dedicated to collect nasal cells. Then the cells will be sent to the lab in order to grow at the air-liquid interface, which is an excellent 'ex vivo' model for their study.

Read the detailed description

The treatment and prevention of respiratory infections caused by emerging viruses or antibiotic-resistant bacteria are major societal and medical challenges. Inhalation allows drugs to be administered in the form of a spray or aerosol, directly into the respiratory tract (nose or lung). This is a validated approach for the non-invasive delivery of drugs to prevent and treat respiratory diseases, particularly infectious ones. Primary human nasal cell cultures grown at the air-liquid interface are an excellent 'ex vivo' model for their study in a physiological and pathophysiological context, and for testing new therapies, including aerosols. In addition, this culture model also offers an alternative to animal experimentation.

The aim of this project is therefore to create a collection of primary cells from the human nasal epithelium.

The main objective is to obtain a minimum of 60 samples of nasal epithelial cells from patients that can be cultured in air-liquid interface. The secondary objectives are to be able to study these nasal cells under physiological and pathophysiological conditions. The cells will first be amplified to constitute a cell biobank. They will then be studied under physiological conditions (anatomical and functional characterisation). Finally, they can be used to establish different models of infection or inflammation, in order to test future aerosol drugs.

02

Conditions studied

  • Nasal Disease

Browse trials for

Keywords

  • nasal cells
  • Respiratory epithelium
03

In context

Nose Diseases

22 studies on the registry are indexed under Nose Diseases; 9 are open to participants now.

This study's planned enrollment of 100 is close to the median of 99 across 18 interventional studies indexed under Nose Diseases.

Browse Nose Diseases studies →

Lead sponsor

University Hospital, Tours is the lead sponsor of 309 studies on the registry; 81 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (age > 18 years) whose native language is French, or who understands French.
  • Affiliation with a French social security system (CMU accepted).
  • , written and signed by the participant.
  • Planned rhinological surgery (meatotomy, septoplasty or turbinoplasty for example, but other surgeries as well)

Exclusion criteria

Exclusion Criteria:

  • Patients under court protection, guardianship or curatorship.
  • Pregnant or breast-feeding women (positive pregnancy test for women of childbearing age).
  • Patients presenting a major alteration of the mucosa or a malignant rhinosinus pathology.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Other
    Patient with programmed surgery

    Patient programmed with surgery of meatotomy, septoplasty or turbinoplasty, or other programmed surgeries

    Other: Collection of nasal cells during programme surgery

Interventions

  • OtherCollection of nasal cells during programme surgery

    During programmed surgery (meatotomy, septoplasty or turbinoplasty for example, or other programmed surgeries), the surgeon will take an atraumatic sample from the nasal cavity using a dedicated device (brush) from the healthy nasal mucosa.

06

What researchers measure

Primary outcomes

  1. Percentage of viability of nasal epithelial cells from the operating room to laboratory

    Collect nasal epithelial cells that can be grown in vitro in an air-liquid interface

    Time frame: 6 hours

Secondary outcomes

  1. Percentage of efficacy of the procedure

    Percentage of samples that can actually be cultivated following transfer to the laboratory.

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
  • AUSSEDAT
    Tours, France
    Recruiting
    • CHARLES AUSSEDAT · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for May 2027, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2024
First posted
May 9, 2024
StartActual
Dec 6, 2024
Primary completionEst.
May 2, 2027
CompletionEst.
May 2, 2028
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06407102
Responsible party
Sponsor
First posted
May 9, 2024
Start date
Dec 6, 2024
Primary completion
May 2, 2027 (estimated)
Completion
May 2, 2028 (estimated)
Last update
Jun 16, 2026

Study contacts

Charles Aussedat, MD
Contact
c.aussedat@chu-tours.fr
0247474747
Adeline Mousset
Contact
a.fourmy@chu-tours.fr
0218370645

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion